{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T07:09:39Z","timestamp":1751699379636},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH\/NHLBI","award":["STIMULUS R25-HL12545"],"award-info":[{"award-number":["STIMULUS R25-HL12545"]}]},{"name":"Northwestern University's Office of the Provost","award":["1406CONFER2122577"],"award-info":[{"award-number":["1406CONFER2122577"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Due to shared modes of transmission, coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is common, and HBV vaccination is recommended for all persons with HCV who remain susceptible to HBV. To identify potential gaps in HBV vaccination among this high-risk population, we aimed to determine the patterns of HBV susceptibility in persons undergoing community-based HCV treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a cross-sectional study within two community-based HCV treatment programs in an urban US setting. Participants were identified for HCV screening and confirmatory testing via street-outreach recruitment directed at persons experiencing homelessness and currently using drugs. Participants were excluded if HBsAg was reactive. Cohort characteristics were obtained via intake surveys and descriptive analysis was performed by exposure status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 150 participants without chronic HBV receiving community-based HCV treatment, 43% had evidence of prior HBV infection, 26% were immune from vaccination, and 31% were non-immune. Among the subset of the cohort reporting current injection drug use (IDU) (<jats:italic>N<\/jats:italic>\u2009=\u2009100), 31% (<jats:italic>n<\/jats:italic>\u2009=\u200910) of those aged 24\u201340 and 47% (<jats:italic>n<\/jats:italic>\u2009=\u200923) of those aged 41\u201357 remained susceptible to HBV infection. By contrast only two participants aged 58\u201374 were HBV non-immune (11%), with 84% immune due to prior exposure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our data reflect a high prevalence of HBV susceptibility among persons undergoing community-based HCV treatment. Although younger patients were more likely to be immune due to vaccination, a high proportion remained non-immune to HBV, particularly among those reporting current IDU. Our data reflect a gap in HBV vaccination among younger persons with HCV and suggest a potential role for co-localizing HBV vaccination with community-based HCV screening and treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-00942-x","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T03:02:56Z","timestamp":1706497376000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High prevalence of hepatitis B virus susceptibility among persons undergoing community-based hepatitis C virus treatment"],"prefix":"10.1186","volume":"21","author":[{"given":"Catherine","family":"Campusano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Kanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"McDonell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer C.","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"issue":"Suppl 1","key":"942_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s12879-017-2775-0","volume":"17","author":"RW Peeling","year":"2017","unstructured":"Peeling RW, Boeras DI, Marinucci F, Easterbrook P. The future of viral hepatitis testing: innovations in testing technologies and approaches. BMC Infect Dis. 2017;17(Suppl 1):699.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"942_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/cid\/ciz001","volume":"69","author":"EU Patel","year":"2019","unstructured":"Patel EU, Thio CL, Boon D, Thomas DL, Tobian AAR. Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011\u20132016. Clin Infect Dis. 2019;69(4):709\u201312. https:\/\/doi.org\/10.1093\/cid\/ciz001.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"942_CR3","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.30297","volume":"69","author":"MG Hofmeister","year":"2019","unstructured":"Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, Edlin BR, Mermin J, Ward JW, Ryerson AB. Estimating prevalence of hepatitis C virus infection in the United States, 2013\u20132016. Hepatology. 2019;69(3):1020\u201331. https:\/\/doi.org\/10.1002\/hep.30297.","journal-title":"Hepatology"},{"issue":"2","key":"942_CR4","first-page":"221","volume":"28","author":"D Konstantinou","year":"2015","unstructured":"Konstantinou D, Deutsch M. The spectrum of HBV\/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol. 2015;28(2):221\u20138.","journal-title":"Ann Gastroenterol"},{"key":"942_CR5","unstructured":"U.S. Department of Health and Human Services.\u00a0Viral Hepatitis National Strategic Plan for the United States: A Roadmap to Elimination (2021\u20132025).\u00a0Washington, DC,\u00a02020. Available at: https:\/\/www.hhs.gov\/sites\/default\/files\/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf. Accessed 20 December 2021"},{"key":"942_CR6","unstructured":"Centers for Disease Control and Prevention. Viral Hepatitis Surveillance\u2014United States, 2018. Available at: https:\/\/www.cdc.gov\/hepatitis\/statistics\/2018surveillance\/index.htm Accessed 13 December 2021"},{"issue":"6","key":"942_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","volume":"4","author":"A Trickey","year":"2019","unstructured":"Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, Leung J, Grebely J, Larney S, Martin NK, Hickman M, Degenhardt L, May MT, Vickerman P. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4(6):435\u201344. https:\/\/doi.org\/10.1016\/S2468-1253(19)30085-8.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"11","key":"942_CR8","doi-asserted-by":"publisher","first-page":"792","DOI":"10.7326\/M17-0377","volume":"166","author":"SJ Bersoff-Matcha","year":"2017","unstructured":"Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, Brinker A. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U. S. food and drug administration adverse event reporting system. Ann Intern Med. 2017;166(11):792\u20138. https:\/\/doi.org\/10.7326\/M17-0377.","journal-title":"Ann Intern Med"},{"issue":"10","key":"942_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.38792.PMID:37862013;PMCID:PMC10589813","volume":"6","author":"MD Morris","year":"2023","unstructured":"Morris MD, McDonell C, Luetkemeyer AF, Thawley R, McKinney J, Price JC. Community-based point-of-diagnosis hepatitis c treatment for marginalized populations: a nonrandomized controlled trial. JAMA Netw Open. 2023;6(10): e2338792. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.38792.PMID:37862013;PMCID:PMC10589813.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"942_CR10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.211783","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski SM, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M. APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325. https:\/\/doi.org\/10.1002\/hep.211783.","journal-title":"Hepatology"},{"issue":"12","key":"942_CR11","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1093\/cid\/ciz669.PMID:31350875;PMCID:PMC7286375","volume":"70","author":"JZ Shing","year":"2020","unstructured":"Shing JZ, Ly KN, Xing J, Teshale EH, Jiles RB. Prevalence of hepatitis B virus infection among US adults aged 20\u201359 years with a history of injection drug use: national health and nutrition examination survey, 2001\u20132016. Clin Infect Dis. 2020;70(12):2619\u201327. https:\/\/doi.org\/10.1093\/cid\/ciz669.PMID:31350875;PMCID:PMC7286375.","journal-title":"Clin Infect Dis"},{"key":"942_CR12","unstructured":"Vaccination Coverage among Adults in the United States, National Health Interview Survey, 2021. Available at: https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/adultvaxview\/pubs-resources\/vaccination-coverage-adults-2021.html#:~:text=Coverage%20with%20at%20least%20one,%E2%80%93September%202021%20(17). Accessed 23 December 2023."},{"key":"942_CR13","unstructured":"Haber P, Schillie S. Epidemiology and Prevention of Vaccine-Preventable Diseases-Hepatitis B. Centers for Disease Control and Prevention, 2021. Available at: https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/hepb.html. Accessed 12 December 2021."},{"issue":"6","key":"942_CR14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/add.14892","volume":"115","author":"D Lewer","year":"2020","unstructured":"Lewer D, Freer J, King E, Larney S, Degenhardt L, Tweed EJ, Hope VD, Harris M, Millar T, Hayward A, Ciccarone D, Morley KI. Frequency of health-care utilization by adults who use illicit drugs: a systematic review and meta-analysis. Addiction. 2020;115(6):1011\u201323. https:\/\/doi.org\/10.1111\/add.14892.","journal-title":"Addiction"},{"issue":"1","key":"942_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/ewjm.172.1.16","volume":"172","author":"KH Seal","year":"2000","unstructured":"Seal KH, Ochoa KC, Hahn JA, Tulsky JP, Edlin BR, Moss AR. Risk of hepatitis B infection among young injection drug users in San Francisco: opportunities for intervention. West J Med. 2000;172(1):16.","journal-title":"West J Med"},{"issue":"1","key":"942_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13104-019-4287-z","volume":"12","author":"CS Hyun","year":"2019","unstructured":"Hyun CS, Lee S, Ventura WR. The prevalence and significance of isolated hepatitis B core antibody (anti-HBc) in endemic population. BMC Res Notes. 2019;12(1):251.","journal-title":"BMC Res Notes"},{"issue":"15","key":"942_CR17","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jama.2023.3692","volume":"329","author":"RL Fleurence","year":"2023","unstructured":"Fleurence RL, Collins FS. A national hepatitis C elimination program in the United States: a historic opportunity. JAMA. 2023;329(15):1251\u20132. https:\/\/doi.org\/10.1001\/jama.2023.3692.","journal-title":"JAMA"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00942-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-00942-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00942-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T19:04:48Z","timestamp":1706555088000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-00942-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["942"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-00942-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"assertion":[{"value":"3 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study data came from two different IRB approvals. The NOW study, participants signed consent; DeLIVER\/HCV Clinic: patients were treated outside of research and Institutional Review Board of the University of California San Francisco approved retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}